



Small Molecule Inhibitors for Cancer Therapy Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2026-01-02	133	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Small Molecule Inhibitors for Cancer Therapy market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Small Molecule Inhibitors for Cancer Therapy market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Small Molecule Inhibitors for Cancer Therapy market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Small Molecule Inhibitors for Cancer Therapy market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global service providers of Small Molecule Inhibitors for Cancer Therapy include Yao Pharma, CHIATAI Tianqing, Zelgen, Simcere, Eisai, CSPC, Novartis, Roche and Jiangxi Shanxiang, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Small Molecule Inhibitors for Cancer Therapy market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Small Molecule Inhibitors for Cancer Therapy.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Small Molecule Inhibitors for Cancer Therapy Market by Company

Yao Pharma

CHIATAI Tianqing

Zelgen

Simcere

Eisai
CSPC
Novartis
Roche
Jiangxi Shanxiang
Pfizer
BEACON Pharma
Bayer
AstraZeneca
Natco Pharma
Cipla
Bristol-Myers Squibb

Small Molecule Inhibitors for Cancer Therapy Segment by Type

Alectinib
Anlotinib
Osimertinib
Lenvatinib
Regorafenib
Sorafenib
Other

Small Molecule Inhibitors for Cancer Therapy Segment by Application

Hospital
Clinic
Other

Small Molecule Inhibitors for Cancer Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Inhibitors for Cancer Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Inhibitors for Cancer Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Inhibitors for Cancer Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Small Molecule Inhibitors for Cancer Therapy companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Small Molecule Inhibitors for Cancer Therapy by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Alectinib
 - 2.2.3 Anlotinib
 - 2.2.4 Osimertinib
 - 2.2.5 Lenvatinib
 - 2.2.6 Regorafenib
 - 2.2.7 Sorafenib
 - 2.2.8 Other
- 2.3 Small Molecule Inhibitors for Cancer Therapy by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Hospital
 - 2.3.3 Clinic
 - 2.3.4 Other
- 2.4 Assumptions and Limitations

3 Small Molecule Inhibitors for Cancer Therapy Breakdown Data by Type

- 3.1 Global Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Type (2027-2032)

4 Small Molecule Inhibitors for Cancer Therapy Breakdown Data by Application

- 4.1 Global Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Small Molecule Inhibitors for Cancer Therapy Market Perspective (2021-2032)
 - 5.2 Global Small Molecule Inhibitors for Cancer Therapy Growth Trends by Region
 - 5.2.1 Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Region (2021-2026)
 - 5.2.3 Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Region (2027-2032)
 - 5.3 Small Molecule Inhibitors for Cancer Therapy Market Dynamics
 - 5.3.1 Small Molecule Inhibitors for Cancer Therapy Industry Trends
 - 5.3.2 Small Molecule Inhibitors for Cancer Therapy Market Drivers
 - 5.3.3 Small Molecule Inhibitors for Cancer Therapy Market Challenges
 - 5.3.4 Small Molecule Inhibitors for Cancer Therapy Market Restraints
-

6 Market Competitive Landscape by Players

6.1 Global Top Small Molecule Inhibitors for Cancer Therapy Players by Revenue

6.1.1 Global Top Small Molecule Inhibitors for Cancer Therapy Players by Revenue (2021-2026)

6.1.2 Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Players (2021-2026)

6.2 Global Small Molecule Inhibitors for Cancer Therapy Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Small Molecule Inhibitors for Cancer Therapy Head Office and Area Served

6.4 Global Small Molecule Inhibitors for Cancer Therapy Players, Product Type & Application

6.5 Global Small Molecule Inhibitors for Cancer Therapy Manufacturers Established Date

6.6 Global Small Molecule Inhibitors for Cancer Therapy Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Small Molecule Inhibitors for Cancer Therapy Market Size (2021-2032)

7.2 North America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026)

7.4 North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Small Molecule Inhibitors for Cancer Therapy Market Size (2021-2032)

8.2 Europe Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026)

8.4 Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size (2021-2032)

9.2 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026)

9.4 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Small Molecule Inhibitors for Cancer Therapy Market Size (2021-2032)

10.2 South America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026)

10.4 South America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

11 Middle East & Africa

11.1 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size (2021-2032)

11.2 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026)

11.4 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

12 Players Profiled

12.1 Yao Pharma

12.1.1 Yao Pharma Company Information

12.1.2 Yao Pharma Business Overview

12.1.3 Yao Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.1.4 Yao Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.1.5 Yao Pharma Recent Developments

12.2 CHIATAI Tianqing

12.2.1 CHIATAI Tianqing Company Information

12.2.2 CHIATAI Tianqing Business Overview

12.2.3 CHIATAI Tianqing Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.2.4 CHIATAI Tianqing Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.2.5 CHIATAI Tianqing Recent Developments

12.3 Zelgen

12.3.1 Zelgen Company Information

12.3.2 Zelgen Business Overview

12.3.3 Zelgen Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.3.4 Zelgen Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.3.5 Zelgen Recent Developments

12.4 Simcere

12.4.1 Simcere Company Information

12.4.2 Simcere Business Overview

12.4.3 Simcere Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.4.4 Simcere Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.4.5 Simcere Recent Developments

12.5 Eisai

12.5.1 Eisai Company Information

12.5.2 Eisai Business Overview

12.5.3 Eisai Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.5.4 Eisai Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.5.5 Eisai Recent Developments

12.6 CSPC

12.6.1 CSPC Company Information

12.6.2 CSPC Business Overview

12.6.3 CSPC Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.6.4 CSPC Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.6.5 CSPC Recent Developments

12.7 Novartis

12.7.1 Novartis Company Information

12.7.2 Novartis Business Overview

12.7.3 Novartis Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.7.4 Novartis Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.7.5 Novartis Recent Developments

12.8 Roche

12.8.1 Roche Company Information

12.8.2 Roche Business Overview

12.8.3 Roche Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.8.4 Roche Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.8.5 Roche Recent Developments

12.9 Jiangxi Shanxiang

12.9.1 Jiangxi Shanxiang Company Information

12.9.2 Jiangxi Shanxiang Business Overview

12.9.3 Jiangxi Shanxiang Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.9.4 Jiangxi Shanxiang Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.9.5 Jiangxi Shanxiang Recent Developments

12.10 Pfizer

12.10.1 Pfizer Company Information

12.10.2 Pfizer Business Overview

12.10.3 Pfizer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.10.4 Pfizer Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.10.5 Pfizer Recent Developments

12.11 BEACON Pharma

12.11.1 BEACON Pharma Company Information

12.11.2 BEACON Pharma Business Overview

12.11.3 BEACON Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.11.4 BEACON Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.11.5 BEACON Pharma Recent Developments

12.12 Bayer

12.12.1 Bayer Company Information

12.12.2 Bayer Business Overview

12.12.3 Bayer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.12.4 Bayer Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.12.5 Bayer Recent Developments

12.13 AstraZeneca

12.13.1 AstraZeneca Company Information

12.13.2 AstraZeneca Business Overview

12.13.3 AstraZeneca Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.13.4 AstraZeneca Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.13.5 AstraZeneca Recent Developments

12.14 Natco Pharma

12.14.1 Natco Pharma Company Information

12.14.2 Natco Pharma Business Overview

12.14.3 Natco Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.14.4 Natco Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.14.5 Natco Pharma Recent Developments

12.15 Cipla

12.15.1 Cipla Company Information

12.15.2 Cipla Business Overview

12.15.3 Cipla Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.15.4 Cipla Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.15.5 Cipla Recent Developments

12.16 Bristol-Myers Squibb

12.16.1 Bristol-Myers Squibb Company Information

12.16.2 Bristol-Myers Squibb Business Overview

12.16.3 Bristol-Myers Squibb Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)

12.16.4 Bristol-Myers Squibb Small Molecule Inhibitors for Cancer Therapy Product Portfolio

12.16.5 Bristol-Myers Squibb Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Small Molecule Inhibitors for Cancer Therapy Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Type (2021-2026)
- Table 7: Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Type (2027-2032)
- Table 9: Global Small Molecule Inhibitors for Cancer Therapy Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Application (2021-2026)
- Table 11: Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Application (2027-2032)
- Table 13: Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region (2021-2026)
- Table 16: Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region (2027-2032)
- Table 18: Small Molecule Inhibitors for Cancer Therapy Industry Trends
- Table 19: Small Molecule Inhibitors for Cancer Therapy Industry Drivers
- Table 20: Small Molecule Inhibitors for Cancer Therapy Industry Opportunities and Challenges
- Table 21: Small Molecule Inhibitors for Cancer Therapy Market Restraints
- Table 22: Global Top Small Molecule Inhibitors for Cancer Therapy Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Players (2021-2026)
- Table 24: Global Small Molecule Inhibitors for Cancer Therapy Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Small Molecule Inhibitors for Cancer Therapy, Headquarters and Area Served
- Table 26: Global Small Molecule Inhibitors for Cancer Therapy Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Small Molecule Inhibitors for Cancer Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Yao Pharma Company Information
- Table 46: Yao Pharma Business Overview

- Table 47: Yao Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 48: Yao Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 49: Yao Pharma Recent Developments
- Table 50: CHIATAI Tianqing Company Information
- Table 51: CHIATAI Tianqing Business Overview
- Table 52: CHIATAI Tianqing Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 53: CHIATAI Tianqing Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 54: CHIATAI Tianqing Recent Developments
- Table 55: Zelgen Company Information
- Table 56: Zelgen Business Overview
- Table 57: Zelgen Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 58: Zelgen Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 59: Zelgen Recent Developments
- Table 60: Simcere Company Information
- Table 61: Simcere Business Overview
- Table 62: Simcere Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 63: Simcere Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 64: Simcere Recent Developments
- Table 65: Eisai Company Information
- Table 66: Eisai Business Overview
- Table 67: Eisai Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 68: Eisai Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 69: Eisai Recent Developments
- Table 70: CSPC Company Information
- Table 71: CSPC Business Overview
- Table 72: CSPC Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 73: CSPC Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 74: CSPC Recent Developments
- Table 75: Novartis Company Information
- Table 76: Novartis Business Overview
- Table 77: Novartis Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 78: Novartis Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 79: Novartis Recent Developments
- Table 80: Roche Company Information
- Table 81: Roche Business Overview
- Table 82: Roche Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 83: Roche Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 84: Roche Recent Developments
- Table 85: Jiangxi Shanxiang Company Information
- Table 86: Jiangxi Shanxiang Business Overview
- Table 87: Jiangxi Shanxiang Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 88: Jiangxi Shanxiang Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 89: Jiangxi Shanxiang Recent Developments
- Table 90: Pfizer Company Information
- Table 91: Pfizer Business Overview
- Table 92: Pfizer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 93: Pfizer Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 94: Pfizer Recent Developments
- Table 95: BEACON Pharma Company Information
- Table 96: BEACON Pharma Business Overview
- Table 97: BEACON Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 98: BEACON Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 99: BEACON Pharma Recent Developments
- Table 100: Bayer Company Information
- Table 101: Bayer Business Overview
- Table 102: Bayer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 103: Bayer Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 104: Bayer Recent Developments
- Table 105: AstraZeneca Company Information
- Table 106: AstraZeneca Business Overview
- Table 107: AstraZeneca Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 108: AstraZeneca Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 109: AstraZeneca Recent Developments
- Table 110: Natco Pharma Company Information
- Table 111: Natco Pharma Business Overview

- Table 112: Natco Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 113: Natco Pharma Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 114: Natco Pharma Recent Developments
- Table 115: Cipla Company Information
- Table 116: Cipla Business Overview
- Table 117: Cipla Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 118: Cipla Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 119: Cipla Recent Developments
- Table 120: Bristol-Myers Squibb Company Information
- Table 121: Bristol-Myers Squibb Business Overview
- Table 122: Bristol-Myers Squibb Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026) & (US\$ Million)
- Table 123: Bristol-Myers Squibb Small Molecule Inhibitors for Cancer Therapy Product Portfolio
- Table 124: Bristol-Myers Squibb Recent Developments
- Table 125: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Small Molecule Inhibitors for Cancer Therapy Product Image
- Figure 5: Global Small Molecule Inhibitors for Cancer Therapy Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Type: 2025 VS 2032
- Figure 7: Alectinib Product
- Figure 8: Anlotinib Product
- Figure 9: Osimertinib Product
- Figure 10: Lenvatinib Product
- Figure 11: Regorafenib Product
- Figure 12: Sorafenib Product
- Figure 13: Other Product
- Figure 14: Global Small Molecule Inhibitors for Cancer Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 15: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Application: 2025 VS 2032
- Figure 16: Hospital Product
- Figure 17: Clinic Product
- Figure 18: Other Product
- Figure 19: Global Small Molecule Inhibitors for Cancer Therapy Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 20: Global Small Molecule Inhibitors for Cancer Therapy Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 21: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region: 2025 VS 2032
- Figure 22: Global Small Molecule Inhibitors for Cancer Therapy Market Share by Players in 2025
- Figure 23: Global Small Molecule Inhibitors for Cancer Therapy Manufacturers Established Date
- Figure 24: Global Top 5 and 10 Small Molecule Inhibitors for Cancer Therapy Players Market Share by Revenue in 2025
- Figure 25: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 26: North America Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: North America Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 28: United States Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Canada Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: Mexico Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 31: Europe Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Europe Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 33: Germany Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: France Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: U.K. Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Italy Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Spain Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Russia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Nordic Countries Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 43: China Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)

- Figure 44: Japan Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: South Korea Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: India Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: India Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 48: Australia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: China Taiwan Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: South America Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: South America Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2021-2032)
- Figure 53: Brazil Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Argentina Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Chile Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 56: Colombia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 57: Peru Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 58: Yao Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 59: CHIATAI Tianqing Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 60: Zelgen Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 61: Simcere Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 62: Eisai Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 63: CSPC Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 64: Novartis Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 65: Roche Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 66: Jiangxi Shanxiang Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 67: Pfizer Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 68: BEACON Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 69: Bayer Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 70: AstraZeneca Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 71: Natco Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 72: Cipla Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)
- Figure 73: Bristol-Myers Squibb Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2021-2026)